

**RICHARD CHARLES OGDEN**

rrooney@san.rr.com

+1 858 531 5013

**EDUCATION:**

1974: B.A. St. Catharine's College  
Cambridge, England  
Natural Sciences (Chemistry)

1977: M.A. Cambridge University  
Cambridge, England  
Chemistry

1977: Ph.D. Cambridge University  
Cambridge, England  
Organic Chemistry

**RESEARCH AND PROFESSIONAL EXPERIENCE:**

2006 - Present Co-Founder, RORR Inc.  
Medical, Scientific Consulting and Education

2001 – 2006 Senior Director  
Scientific Affairs, HIV  
US Medical  
Pfizer Inc.

1998 - 2001 Senior Director  
Scientific Development  
Agouron Pharmaceuticals, Inc.  
La Jolla, California

1995 - 1998 Director  
Scientific Development  
Agouron Pharmaceuticals, Inc.  
La Jolla, California

1991 - 1994: Principal Scientist  
Manager, New Projects Research  
Agouron Pharmaceuticals, Inc.  
La Jolla, California

1989-1991: Group Leader - Medicinal Chemistry  
Agouron Pharmaceuticals, Inc.  
La Jolla, California

1984-1989: Senior Scientist  
Agouron Pharmaceuticals, Inc.  
La Jolla, California

1983-1989: Research Scientist  
The Agouron Institute  
La Jolla, California

1981-1983: Assistant Research Chemist  
University of California, San Diego  
La Jolla, California

1980-1981: Visiting Scientist  
City of Hope Hospital  
Duarte, California

1977-1980: Postdoctoral Chemist  
University of California, San Diego  
La Jolla, California

1974-1977: Postgraduate Chemist  
University Chemical Laboratory  
Cambridge University  
Cambridge, England

## **PATENTS**

1. J. Ernest Villafranca, Richard C. Ogden, Louise Slade, Harold I. Levine, Timothy W. Schenz and Ronald G. Yarger 1989 (CIP 1990) Ice Crystal Control Peptides and Recombinant DNA Mediated Production Thereof. US 07/394,881
2. Laura A. Bloom, Theodore J. Boritzki, Richard Ogden and Patrick O'Connor 2003/4 Combination Therapy for Treating Methylthioadenosine Phosphorylase Deficient Cells US 2004-0043959; WO 03/074083

## **PUBLICATIONS**

1. Skowron, G. and Ogden, R. eds. HIV-1 Reverse Transcriptase Inhibitors and AIDS Therapy. Humana Press 2006
2. Katzenstein, D. and Ogden, R. (2005) Protease in CRF02\_AG Viruses. Clin. Inf. Disease **41** 252-254
3. Skowron, G ; Leung, G ; Hall, D.B; Robinson, P ; Lewis, R; Grosso, R; Jacobs,

- M; Kerr, B.; Macgregor T.; Stevens M; Fisher, A.; Ogden, R., and Liberman-Yen, B. (2004) Pharmacokinetic Evaluation and Short Term Activity of Stavudine, Nevirapine, and Nelfinavir Therapy in HIV Infected Adults *J. Aids* **35** 351-358
4. Ogden, R. (2003) HIV Protease Inhibitors In *Viral Infections and Treatment* eds. Rubsamen-Waigmann, H.; Deres, K.; Hewlett, G. and Welker, R. Marcel Dekker (New York).
  5. Kravcik, S., Magill, A, Sanghvi, B, Ogden, R, Cameron, D.W, Lewis, R., Yu, G., and Badley, A.D. (2001) Comparative CD4 T-Cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. *HIV Clinical Trials* **2** 160-170
  6. Ogden, Richard C. and Flexner, Charles W. eds. *HIV-1 Protease Inhibitors and AIDS Therapy*. Marcel Dekker (New York) 2001
  7. Decamp, D., Ogden, R., Kuntz, I., and Craik, C. (1996) Site-Directed Drug Design. In *Protein Engineering: Principles and Practice*, eds. Cleland, J. L. and Craik, C. S. Wiley-Liss, Inc.
  8. Gehlhaar, D. et al. (1995). De Novo Design of Enzyme Inhibitors by Monte Carlo Ligand Generation. *J. Med. Chem.* **38**, 466-472.
  9. Reece, L. J., Nichols, R., Ogden, R. C. and Howell, E. E. (1991) Construction of a Synthetic Gene for an R-Plasmid Encoded DHFR and Studies on the Role of the N-terminus in the Protein, *Biochemistry* **30**, 10895.
  10. Appelt et al (1991) Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis, *J. Med. Chem.* **34**, 1925
  11. Hecht, M., Richardson, J.S., Richardson, D., and Ogden, R.C. 1990. De novo design, expression and characterization of felix: a four-helix bundle protein of native-like sequence. *Science* **249**:884-891.
  12. Hostomsky Z., K. Appelt and R. C. Ogden 1989. High Level Expression of Protease from HIV-1 in *E. coli* using a Synthetic Gene. *Biochem Biophys Res. Commun.* **161**:1056-1063.
  13. Ogden, R. C. and D. A. Adams (1989). Recombinant DNA Technology. In: *Biochemistry*, Rawn, Patterson Press, Carolina Biological Supply Co.
  14. Ogden, R. C. and D. A. Adams. 1987. Electrophoresis in Agarose and Acrylamide Gels. *Guide to Molecular Cloning Techniques, Methods in Enzymology* **152**:61-87 Academic Press
  15. Normanly, J., R. C. Ogden, S. J. Horvath, and J. Abelson. 1986. Changing the identity of a transfer RNA. *Nature* **321**:213-219.
  16. Lundwall, A., R. A. Wetsel, T. Kristensen, A. S. Whitehead, E. E. Woods, R. C. Ogden, H. R. Colten and B. F. Tack. 1985. Isolation and sequence analysis of a cDNA clone encoding the fifth complement component. *J. Biol. Chem.* **260**:2108-2112. 23.
  17. Ogden, R., M-C. Lee and G. Knapp. 1984. Transfer RNA splicing in *Saccharomyces cerevisiae*: Defining the substrates. *Nucleic Acids Res.* **12**:9367-9382.
  18. Villafranca, J. E., E. E. Howell, D. H. Voet, M. S. Strobel, R. C. Ogden, J. Abelson and J. Kraut. 1983. Directed mutagenesis of dihydrofolate reductase. *Science* **222**:782-788.
  19. Williams, J., L. Steiner, R. Ogden, M. Simon and G. Feher. 1983. Primary structure

- of the M subunit of the reaction center from *Rhodospseudomonas sphaeroides*. *Proc. Natl. Acad. Sci. USA* **80**:6505-6509.
20. Newman, A. J., R. C. Ogden and J. Abelson. 1983. tRNA gene transcription in yeast: effects of specified base substitutions in the intragenic promoter. *Cell* **22**:117-125.
  21. Mattocia, E., M. I. Baldi, G. Pande, G. P. Tocchini-Valentini and R. C. Ogden. 1983. Mutation in the A block of a yeast tRNA<sup>leu</sup> gene that allows transcription but abolishes splicing and 5' end maturation. *Cell* **22**:67-76.
  22. Tocchini-Valentini, G. P., E. Mattocia, M. I. Baldi, R. Ogden and G. Pande. 1982. Role of tRNA gene structure in transcription and processing. *Cold Spring Harbor Symposia on Quantitative Biology XLVIII* 885-892.
  23. Reilly, J. G., R. C. Ogden and J. J. Rossi. 1982. Isolation of a mouse pseudo tRNA gene that encodes CCA: A possible example of reverse flow of genetic information. *Nature* **300**:287-287.
  24. Cohn, D. H., R. C. Ogden, J. N. Abelson, T. O. Baldwin, K. H. Neelson, M. I. Simon and A. J. Mileham. 1983. Cloning of the *Vibrio harveyi* luciferase genes: Use of a synthetic oligonucleotide probe. *Proc. Natl. Acad. Sci. USA* **80**:120-123.
  25. Ogden, R. C., G. Knapp, C. L. Peebles, J. D. Johnson and J. Abelson. 1981. The mechanisms of tRNA splicing. *Trends in Biochemical Sciences* **6**:154-157.
  26. Abelson, J., G. Knapp, C. L. Peebles, R. C. Ogden, P. F. Johnson and J. D. Johnson. 1981. tRNA splicing in yeast. In: *Molecular and Cellular Aspects of Microbial Evolution*, Cambridge University Press, pp. 151-173.
  27. Brown, D. M. and R. C. Ogden. 1981. A synthesis of pseudouridine. *J.C.S. Perkin I*:723-725.
  28. Kang, H. S., R. C. Ogden and J. Abelson. 1980. Two yeast tRNA genes containing intervening sequences. In: *Mobilization and Reassembly of Genetic Information*, Academic Press, pp. 317-334.
  29. Schmidt, O., J. Mao, R. C. Ogden, J. S. Beckmann, H. Sakano, J. Abelson and D. Soll. 1980. Dimeric tRNA precursors in yeast. *Nature* **287**:750-752. 10.
  30. Johnson, J. D., R. C. Ogden, P. F. Johnson, J. Abelson, P. Dembeck and K. Itakura. 1980. Transcription and processing of a yeast tRNA gene containing a modified intervening sequence. *Proc. Natl. Acad. Sci. USA* **77**:2564-2568.
  31. Ogden, R. C., G. Knapp, C. L. Peebles, H. S. Kang, J. S. Beckman, P. F. Johnson, S. A. Fuhrman and J. Abelson. 1980. Enzymatic removal of intervening sequences in the synthesis of yeast tRNAs. In: *tRNA, Biological Aspects*, D. Soll, P. Schimmel and J. Abelson, eds., Cold Spring Harbor Laboratory, pp. 173-190.
  32. Kang, H. S., R. C. Ogden, G. Knapp, C. L. Peebles and J. Abelson. 1979. Structure of yeast tRNA precursors containing intervening sequences. In: *Eukaryotic Gene Regulation*, Academic Press, pp. 69-84.
  33. Knapp, G., R. C. Ogden, C. L. Peebles and J. Abelson. 1979. Splicing of yeast tRNA precursors: Structure of the reaction intermediates. *Cell* **18**:37-45.
  34. Peebles, C. L., R. C. Ogden, G. Knapp and J. Abelson. 1979. Splicing of yeast tRNA precursors: A two stage reaction. *Cell* **18**:27-35.
  35. Ogden, R. C., J. S. Beckmann, J. Abelson, H. S. Kang, D. Soll and O. Schmidt. 1979. *In vitro* transcription and processing of a yeast tRNA gene containing and intervening sequence. *Cell* **17**:399-406.

36. Beckmann, J. S., P. F. Johnson, G. Knapp, H. Sakano, S. A. Fuhrman, R. C. Ogden and J. Abelson. 1978. Organization and expression of yeast tRNA genes. In: *Nonsense Mutations and tRNA Suppressors*, J. E. Celis and J. D. Smith, eds. pp. 207-234.
37. Brown, D. M., S. D. Bridges, R. C. Ogden and R. P. L. Conrad. 1978. The synthesis of isomeric 2'-deoxypseudouridines. *Nucleic Acids Research* special publication no. 4. S121-S1232.
38. Ogden, R. C., Ph.D. Thesis, Cambridge University 1977. Synthesis in the Pseudouridine Series.
39. Bridges, S. D., D. M. Brown and R. C. Ogden. 1977. 2'-Deoxypseudouridine. *J.C.S. Chem. Commun.* 460-461.

### **Richard Ogden Ph.D.**

Since leaving Pfizer in April 2006, Dr. Ogden co-founded RORR Inc., a Medical, Scientific Consulting and Education company with current US and European-based clients. Areas of corporate focus include: viral infectious diseases (HIV, Hepatitis C, Respiratory viruses) • strategic planning for clinical research programs • product development in the antiviral and oncology therapeutic areas • biological product development in the analytical reagents and tools area • manufacturing and engineering liaison • intellectual property consultancy • technology feasibility assessment • legal consultancy • continuing medical education and scientific education for professionals and non-scientists. • fund raising on behalf of new biotechnology companies. Clients include new pharmaceutical companies developing novel HIV and HCV drugs and the International Aids society.

He joined Agouron Pharmaceuticals, Inc. as a founding scientist at its inception in 1984, where he held positions of Group Leader of Medicinal Chemistry, Principal Scientist, and Senior Director of Scientific Development. He was a team member in the HIV project which led to the discovery and development of Nelfinavir (Viracept®). Responsibilities in Scientific Development included presenting Agouron R&D activities to potential corporate partners and investors, assessing technology and compound acquisitions, organizing the process by which new drug targets were selected and projects initiated, and communicating research and clinical activities to clinicians, other healthcare providers and patient groups.

He served as the scientific liaison for the Agouron/Pfizer commercial and corporate organizations following the merger with Pfizer, and his principal responsibilities have included assisting in the continued support of the protease inhibitor Nelfinavir, by providing medical education, including CME certified presentations, within the HIV/AIDS clinical and patient communities, and in the evaluation of proposals for post marketing clinical research in the HIV/AIDS area. He also supported the pre-marketing activities for many clinical agents in the HIV/AIDS and oncology therapeutic areas. With Pfizer, he had an additional opportunity to work with the Pfizer Foundation in its support of the Academic Alliance and its efforts in Uganda, and with Corporate

Philanthropy, in its support of the World Economic Forum and the Global Business Council. He also had the opportunity to advise and brief the CEO, Hank McKinnell, during his membership of the Presidential Advisory Commission on HIV/AIDS. He served with both Agouron and Pfizer as the representative on the International AIDS Society Industry Liaison Forum. In addition to numerous publications, he is co-editor, with Charles Flexner, on a book on Protease Inhibitors in AIDS Therapy and with Gail Skowron, on a book on Reverse Transcriptase Inhibitors in AIDS Therapy.

He received his bachelor's degree in natural sciences and doctorate in synthetic organic chemistry with Dr. Dan Brown at Cambridge University. His academic career started with postdoctoral research studying RNA transcription and processing at the University of California, San Diego in the laboratory of Professor John Abelson, following which he undertook independent research, funded by the National Science Foundation, in the area of protein and RNA structure-function relationships at the University of California, San Diego and the Agouron Institute.